Nov 14, 2022 / 03:00AM GMT
Operator
Hello, and good morning. Welcome to Aurobindo Pharma Quarter 2 FY '23 Earnings Call. (Operator Instructions)
Please note that this conference is being recorded. I now hand the conference over to Deepti Thakur for the opening remarks. Thank you, and over to you.
Deepti Thakur -
Thank you, Aditya. Good morning, and a warm welcome to our second quarter FY '23 earnings call. I'm Deepti Thakur from the Investor Relations team. I would like to introduce my senior management team today on the call with us, represented by Dr. Satakarni Makkapati, CEO of Aurobindo Biosimilars, Vaccine and Peptides business; Mr. Yugandhar Puvvala, CEO of Eugia Pharma Specialities Limited; Mr. Sanjeev Dani, COO and Head Formulations Aurobindo Pharma Limited; Mr. S. Subramanian, CFO; and Mr. Swami Iyer, CEO of Aurobindo Pharma USA.
We will begin the call with summary highlights from the management followed by an interactive Q&A session. Please note that some of the matters we will discuss today are forward-looking, including and without limitations, statements relating to the
Q2 2023 Aurobindo Pharma Ltd Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot